The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.

You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be

Study Name on
ClinicalTrials.gov (link is external)
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Study DrugVX-121/TEZ/D-IVA
Type of Study DrugCFTR Modulation
Study TitleA Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Study Phase33
Study SponsorVertex

Link on
clinicaltrials.gov (link is external)

https://clinicaltrials.gov/ct2/show/NCT05033080 

Participating ECFS-CTN sitesPlease contact ecfs-ctn@uzleuven.be for most recent sitelist
AgePediatric and Adult patients